Cliff Asness's ARQT Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 468,253 shares of Arcutis Biotherapeutics, Inc. (ARQT) worth $11.03 M, representing 0.01% of the portfolio. First purchased in 2023-Q4, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in ARQT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 226,258 shares. Largest reduction occurred in Q1 2024, reducing 257,989 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Arcutis Biotherapeutics (ARQT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arcutis Biotherapeutics (ARQT) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -31,165 | Reduce 6.24% | 468,253 | $23.56 |
| Q4 2025 | +58,103 | Add 13.17% | 499,418 | $29.04 |
| Q3 2025 | +66,082 | Add 17.61% | 441,315 | $18.85 |
| Q2 2025 | +127,037 | Add 51.18% | 375,233 | $14.02 |
| Q1 2025 | +43,716 | Add 21.38% | 248,196 | $15.64 |
| Q4 2024 | -47,671 | Reduce 18.91% | 204,480 | $13.93 |
| Q3 2024 | -5,206 | Reduce 2.02% | 252,151 | $9.30 |
| Q2 2024 | +226,258 | Add 727.54% | 257,357 | $9.30 |
| Q1 2024 | -257,989 | Reduce 89.24% | 31,099 | $9.91 |
| Q4 2023 | +289,088 | New Buy | 289,088 | $3.23 |
Cliff Asness's Arcutis Biotherapeutics Investment FAQs
Cliff Asness first purchased Arcutis Biotherapeutics, Inc. (ARQT) in Q4 2023, acquiring 289,088 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Arcutis Biotherapeutics, Inc. (ARQT) for 10 quarters since Q4 2023.
Cliff Asness's largest addition to Arcutis Biotherapeutics, Inc. (ARQT) was in Q4 2023, adding 289,088 shares worth $933,754.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 468,253 shares of Arcutis Biotherapeutics, Inc. (ARQT), valued at approximately $11.03 M.
As of the Q1 2026 filing, Arcutis Biotherapeutics, Inc. (ARQT) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Arcutis Biotherapeutics, Inc. (ARQT) was 499,418 shares, as reported at the end of Q4 2025.